KYMR
Kymera Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.49 / 10
Netural
Analyst consensus is bullish (66.7% Strong Buy, 33.3% Buy) yet recent performance is poor, with price down 6.68% and mixed win rates. Fund‑flow score is 8.0/10, showing strong overall inflows except a slight outflow in the extra‑large segment.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
33%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-26
InstitutionPiper Sandler
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for KYMR?
- KYMR holds a Bearish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.49/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
